Search results
Researchers identify important gene in the fight against prostate cancer
Medical Xpress· 1 day agoLoss of the KMT2C gene increases the risk of developing metastases. Prostate cancer is the second...
Earnings call: Celcuity reports Q1 financials, advances in cancer trials By Investing.com
Investing.com· 1 day agoThe company reported a net loss of $21.6 million, which is a significant increase from the $11.9...
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
WPRI Providence· 4 days agoThe volume of data being presented by Astellas reinforces its commitment to changing the course of cancer treatment through targeted therapies for hard-to-treat cancers ...
Q1 2024 Panbela Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 1 day agoWe also entered into a clinical trial agreement for a Phase II trial of eflornithine in castration-resistant metastatic prostate cancer
Candel Lights Up Investors' Portfolio With 830% Gain
RTT News· 2 days agoShares of Candel Therapeutics Inc. (CADL) have gained more than 830% in the past 2 months, thanks to the substantial progress achieved across its clinical programs.
New research and treatment advances from Yale Canc | Newswise
Newswise· 5 days agoNearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts
Myriad Genetics (NASDAQ:MYGN) Hits New 52-Week High at $24.92
ETF DAILY NEWS· 6 days agoMyriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $24.92 and last traded at $24.45 ...
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Motley Fool via Yahoo Finance· 5 days agoCabometyx is still being tested in various clinical trials, which could allow it to grind out new...
Q2 2024 EPS Estimates for Janux Therapeutics, Inc. Raised by Wedbush (NASDAQ:JANX)
ETF DAILY NEWS· 5 days agoJanux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Equities research analysts at Wedbush upped their Q2 2024 EPS estimates for Janux Therapeutics in a research note issued on Wednesday, ...
MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman
Morningstar· 7 days agoSAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.
